- $2.08bn
- $1.59bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.91 | ||
| Price to Tang. Book | 5.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -192.05% | ||
| Return on Equity | -198.83% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 22.52 | 109.27 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 1970
- Public Since
- September 23rd, 2022
- No. of Shareholders
- 51
- No. of Employees
- 256
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 102,064,999
- Address
- 215 Church Street, NEW HAVEN, 06510
- Web
- https://www.biohaven.com/
- Phone
- +1 2034040410
- Contact
- Jennifer Porcelli
- Auditors
- Ernst & Young LLP
Upcoming Events for BHVN
Similar to BHVN
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
FAQ
As of Today at 19:36 UTC, shares in Biohaven are trading at $20.37. This share price information is delayed by 15 minutes.
Shares in Biohaven last closed at $20.37 and the price had moved by -53.74% over the past 365 days. In terms of relative price strength the Biohaven share price has underperformed the S&P500 Index by -56.5% over the past year.
The overall consensus recommendation for Biohaven is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiohaven does not currently pay a dividend.
Biohaven does not currently pay a dividend.
Biohaven does not currently pay a dividend.
To buy shares in Biohaven you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $20.37, shares in Biohaven had a market capitalisation of $2.08bn.
Here are the trading details for Biohaven:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BHVN
Based on an overall assessment of its quality, value and momentum Biohaven is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biohaven is $60.46. That is 196.81% above the last closing price of $20.37.
Analysts covering Biohaven currently have a consensus Earnings Per Share (EPS) forecast of -$6.83 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biohaven. Over the past six months, its share price has underperformed the S&P500 Index by -57.38%.
As of the last closing price of $20.37, shares in Biohaven were trading -47.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biohaven PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Biohaven's directors